Switching to insulin glargine 300 units/mL in real‐world older patients with type 2 diabetes (DELIVER 3)

Autor: Timothy S. Bailey, Jasmanda Wu, Rishab Gupta, John Van Vleet, Arjun A. Menon, Fang L. Zhou, Lawrence Blonde, Paulos Berhanu, Jukka Westerbacka
Jazyk: angličtina
Rok vydání: 2019
Předmět:
Male
medicine.medical_specialty
endocrine system diseases
Endocrinology
Diabetes and Metabolism
Insulin Glargine
030209 endocrinology & metabolism
Type 2 diabetes
030204 cardiovascular system & hematology
Rate ratio
03 medical and health sciences
0302 clinical medicine
Endocrinology
Internal medicine
Internal Medicine
medicine
Humans
insulin glargine 300 units/mL
Insulin detemir
Aged
Retrospective Studies
Aged
80 and over
Glycated Hemoglobin
Insulin glargine
business.industry
Incidence (epidemiology)
Hazard ratio
nutritional and metabolic diseases
Original Articles
medicine.disease
Hypoglycemia
Hospitalization
Basal (medicine)
Diabetes Mellitus
Type 2
real‐world study
Original Article
Female
type 2 diabetes
business
hormones
hormone substitutes
and hormone antagonists
medicine.drug
Cohort study
hypoglycaemia
Zdroj: Diabetes, Obesity & Metabolism
ISSN: 1463-1326
1462-8902
Popis: Aim To compare the second‐generation basal insulin glargine 300 units/mL (Gla‐300) and first‐generation basal insulins on glycaemic control and hypoglycaemia risk in older adults with type 2 diabetes (T2D). Materials and methods DELIVER 3 was a retrospective observational cohort study of electronic medical records. A total of 1176 older adults (aged ≥ 65 years) with T2D and ≥1 HbA1c value during 6 month baseline and 3 to 6 month follow‐up who switched from basal insulin to Gla‐300 were propensity score‐matched to 1176 older adults who switched to a first‐generation basal insulin [insulin detemir (IDet) or insulin glargine 100 units/mL (Gla‐100)]. Outcomes were follow‐up HbA1c, achievement of HbA1c
Databáze: OpenAIRE
Externí odkaz: